RECRUITING

Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in patients receiving Chimeric antigen receptor (CAR) T therapy and determine the correlation between immune profile and disease relapse/resistance in CAR T therapy.

Official Title

Mechanisms of Disease Relapse/Resistance in CAR T Therapy for Hematologic Malignancies

Quick Facts

Study Start:2022-05-27
Study Completion:2025-11-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05397132

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.
  2. 2. Has a confirmed diagnosis of hematologic malignancy and will be undergoing CAR T therapy with commercial CAR T product.
  3. 3. Patient who has a confirmed diagnosis of hematologic malignancy and will be receiving CAR T therapy under clinical trial protocol will also be eligible if the clinical trial sponsor and the investigator approve patient participation in the study.
  1. * NA

Contacts and Locations

Study Contact

Quinna Lawson
CONTACT
919-681-3095
quinna.marshburn@duke.edu
Peggy Alton
CONTACT
919-684-9220
peggy.alton@duke.edu

Principal Investigator

Yubin Kang
PRINCIPAL_INVESTIGATOR
Duke University

Study Locations (Sites)

Duke University
Durham, North Carolina, 27710
United States

Collaborators and Investigators

Sponsor: Duke University

  • Yubin Kang, PRINCIPAL_INVESTIGATOR, Duke University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-05-27
Study Completion Date2025-11-01

Study Record Updates

Study Start Date2022-05-27
Study Completion Date2025-11-01

Terms related to this study

Keywords Provided by Researchers

  • CAR-T

Additional Relevant MeSH Terms

  • Hematologic Malignancy